GlaxoSmithKline (GSK) has submitted marketing authorisation application, to the European Medicines Agency, for trametinib (MEK) as monotherapy and dabrafenib (BRAF)/MEK combination therapy in metastatic melanoma. The application was ...
Tags: GSK, metastatic melanoma therapy, Medicines